Table 2.

Percents Susceptible (%) of FQR Urinary Tract Pathogens (n=1,100)

Organism* (FQR N/Total N Tested)	AK	A/S	CPE	CTF	CFX	CAZ	CAX	ETP	IMP	P/T
A. baumannii (30/57)	37	23	7	3	na	7	7	na	43	10
C. freundii (5/50)	100	20	80	40	0	40	40	80	80	60
E. aerogenes (2/58)	100	0	50	0	50	0	0	50	100	50
E. cloacae (23/140)	83	0	57	4	4	17	4	35	100	26
E. coli (763/2163)	93	14	65	55	76	56	56	96	99	86
ESBL+ (300/367)	88	7	12	0	74	0	0	95	100	81
ESBL− (463/1796)	97	19	99	91	77	92	92	97	99	89
K. oxytoca (8/86)	87	0	38	25	87	25	25	87	100	38
ESBL+ (6/13)	83	0	17	0	83	0	0	83	100	17
ESBL− (2/73)	100	0	100	100	100	100	100	100	100	100
K. pneumoniae (96/582)	74	4	26	18	48	21	17	57	79	34
ESBL+ (65/135)	78	0	8	0	51	0	0	55	88	25
ESBL− (31/447)	65	13	65	55	42	65	52	61	61	52
M. morganii (8/49)	100	0	38	38	50	50	38	100	50	100
P. mirabilis (38/209)	84	37	81	55	73	60	55	100	27	90
ESBL+ (10/18)	60	30	40	0	80	0	0	100	20	100
ESBL− (28/191)	93	39	96	75	71	82	75	100	29	86
P. aeruginosa (124/295)	62	na	31	7	na	49	8	na	54	73
S. marcescens (3/47)	67	0	67	0	0	67	33	67	67	33
All FQR Isolates Combined (1100/3781)	86	13	56	44	61	57	44	78	88	76

^*C. koseri (n=45) not included as all were fluoroquinolone-susceptible.

AK, Amikacin; A/S, Ampicillin-Sulbactam; CPE, Cefepime; CTF, Cefotaxime; CFX, Cefoxitin; CAZ, Ceftazidime; CAX, Ceftriaxone; ETP, Ertapenem; IMP, Imipenem; P/T, Piperacillin-Tazobactam. na, CLSI breakpoints not available for this species/drug combination (na’s were calculated as resistant for purposes of Grand Total percentages).